Tolerance Bio is developing therapies that manipulate immune tolerance by preserving and restoring thymus function, which is critical for regulating immune responses. The company targets immune-mediated diseases, aiming to enhance health span through thymus-based interventions.
Funding
$20.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Immune-mediated diseases arise from a dysregulated immune system, where the body attacks its own tissues. Current treatments often suppress the immune system broadly, leading to increased risk of infection and other side effects, without addressing the underlying cause of immune dysregulation. A more targeted approach is needed to restore immune tolerance and resolve the root cause of these diseases.
Solution
Tolerance Bio is developing therapies focused on modulating the thymus, the primary organ responsible for establishing immune tolerance. Their approach aims to restore and preserve thymus function, enabling the body to re-establish self-tolerance and prevent autoimmune attacks. By targeting the thymus, Tolerance Bio seeks to develop therapies that address the fundamental mechanisms of immune-mediated diseases, offering a more targeted and potentially curative approach compared to broad immunosuppression. This strategy has the potential to enhance health span by promoting a balanced and well-regulated immune system.
Target Audience
The primary target audience includes individuals suffering from immune-mediated diseases, as well as healthcare providers specializing in immunology and autoimmune disorders.
Features
- Development of thymus-based interventions to restore immune tolerance.
- Targeted approach to address the underlying cause of immune-mediated diseases.
- Therapies designed to enhance health span through immune system regulation.